Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Sanofi-aventis And Regeneron Announce Results From Phase 2 Study With Aflibercept (VEGF Trap) In Advanced Ovarian Cancer
Sanofi Aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that advanced ovarian cancer patients with recurrent symptomatic malignant ascites (SMA) receiving aflibercept (VEGF Trap) in a randomized, placebo-controlled Phase 2 study experienced a statistically significant improvement in the primary study endpoint, mean time to first repeat paracentesis (removal of fluid from the abdominal cavity), versus placebo control. Symptomatic malignant ascites is an abnormal build-up of fluid in the abdominal cavity in patients with advanced cancer.
generic viagra online
Measurements Fail To Identify TB Patients Who Could Benefit From Shorter Treatment Course
Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in re-limited settings with poor public health infrastructures.
News of the day
Universal Sensors, Nottingham Trent University And Cambridge Design Partnership To Help In The Fight Against The Hospital Superbugs, C.difficile, MRSA
Universal Sensors Ltd (Cambridge, UK), Nottingham Trent University (Nottingham, UK) and Cambridge Design Partnership (Cambridge, UK) have entered into a strategic alliance to develop a hand-held system to detect the hospital superbugs, C.difficile and MRSA. The collaboration is funded through the new Small Business Research Initiative (SBRI), in contracts that were awarded by the National Institute for Health Research (NIHR) under its Invention for Innovation (i4i) Programme, the results of which were announced on 15th May 2009.
Public Health

Miami-Dade, Blue Cross Announce Low-Cost PPO Aimed At County's Uninsured

Florida"s Miami-Dade County and BlueCross BlueShield of Florida on Tuesday announced a new low-cost health plan, called Miami-Dade Blue, aimed at helping the estimated 600,000 uninsured county residents, the Miami Herald reports. The plan -- which costs taxpayers nothing -- is a traditional PPO, with no pre-approvals or referrals and will cost a healthy 35-year-old male about $100 per month. Miami-Dade Blue has a $250 deductible and will cover 90% of in-network hospital costs and 100% of fees for in-network lab tests after the deductible is met. The copayment for generic drugs is $10 per prescription; the plan will not offer coverage for brand-name prescriptions.The plan is being offered to individuals younger than age 65 and to small employers with up to 50 workers. Businesses will be guaranteed coverage if 70% of employees take part in the plan and the owner pays at least 50% of the premiums; however, individuals with costly pre-existing health conditions likely will be denied coverage. The plan has an annual out-of-pocket limit of $2,500 and a lifetime benefit of $5 million. About 1,500 physicians agreed to be part of the Miami-Dade Blue network, while 20 clinics and seven hospitals are in the plan"s network (Dorschner, Miami Herald, 5/27). Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009